Orthofix Medical commenced full market release and first implants of Legacy Demineralized Bone Matrix (DBM), a putty for filling voids or gaps in bony defects or traumatic injuries of the spine, pelvis or extremities. Legacy DBM is processed by MTF Biologics to preserve the inherent growth factors natural to the bone.
Legacy DBM has a puttylike consistency that features desirable handling and can be used as an extender with autograft or allograft or with bone marrow aspirate.
A complementary addition to the biologics offered by Orthofix through its exclusive partnership with MTF Biologics, Legacy DBM joins the recently introduced Virtuos™ Lyograft, Trinity Elite™, FiberFuse™ Advanced and FiberFuse Strip allografts, and the AlloQuent™ structural allograft portfolio. In addition to the MTF Biologic solutions, Orthofix proudly markets and distributes the Opus™ BA bioactive bone graft, Opus Mg Set bone void filler, Opus One osteoconductive scaffold, and the O-Genesis™ graft delivery system. This comprehensive portfolio gives surgeons the ability to select the best option to meet their procedural and patient needs.
Orthofix President of Global Spine Kevin Kenny said, “In the past year alone, we have introduced five new biologics including the Virtuos™ Lyograft, a first-of-its-kind, shelf-stable, and complete autograft substitute. In addition, we recently announced a partnership with CGBio, a developer of innovative bone grafts, representing the first step in bringing Novosis™ – the next evolution in bone growth factor technology – to the U.S. and Canadian markets.”
Orthofix Medical commenced full market release and first implants of Legacy Demineralized Bone Matrix (DBM), a putty for filling voids or gaps in bony defects or traumatic injuries of the spine, pelvis or extremities. Legacy DBM is processed by MTF Biologics to preserve the inherent growth factors natural to the bone.
Legacy DBM has a...
Orthofix Medical commenced full market release and first implants of Legacy Demineralized Bone Matrix (DBM), a putty for filling voids or gaps in bony defects or traumatic injuries of the spine, pelvis or extremities. Legacy DBM is processed by MTF Biologics to preserve the inherent growth factors natural to the bone.
Legacy DBM has a puttylike consistency that features desirable handling and can be used as an extender with autograft or allograft or with bone marrow aspirate.
A complementary addition to the biologics offered by Orthofix through its exclusive partnership with MTF Biologics, Legacy DBM joins the recently introduced Virtuos™ Lyograft, Trinity Elite™, FiberFuse™ Advanced and FiberFuse Strip allografts, and the AlloQuent™ structural allograft portfolio. In addition to the MTF Biologic solutions, Orthofix proudly markets and distributes the Opus™ BA bioactive bone graft, Opus Mg Set bone void filler, Opus One osteoconductive scaffold, and the O-Genesis™ graft delivery system. This comprehensive portfolio gives surgeons the ability to select the best option to meet their procedural and patient needs.
Orthofix President of Global Spine Kevin Kenny said, “In the past year alone, we have introduced five new biologics including the Virtuos™ Lyograft, a first-of-its-kind, shelf-stable, and complete autograft substitute. In addition, we recently announced a partnership with CGBio, a developer of innovative bone grafts, representing the first step in bringing Novosis™ – the next evolution in bone growth factor technology – to the U.S. and Canadian markets.”
Copy to clipboard 
